Visit-to-Visit Glucose Variability, Cognition, and Global Cognitive Decline : The Multi-Ethnic Study of Atherosclerosis
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
CONTEXT: Higher visit-to-visit glucose variability (GV) is associated with dysglycemia and type 2 diabetes (T2D), key risk factors for cognitive decline.
OBJECTIVE: Evaluate the association of GV with cognitive performance and decline in racially/ethnically diverse older populations with and without T2D.
METHODS: We calculated the standard deviation of glucose (SDG), average real variability (ARV), and variability independent of the mean (VIM) among 4367 Multi-Ethnic Study of Atherosclerosis participants over 6 clinical examinations. Participants completed a cognitive assessment at the fifth examination, and a subset completed a second assessment 6 years later. We used multivariable linear regression to estimate the association of intraindividual GV with cognitive test scores after adjustments for cardiovascular risk factors and mean glucose level over the study period.
RESULTS: Two-fold increments in the VIM and SDG were associated with worse Cognitive Abilities Screening Instrument (CASI) performance, while two-fold increments in VIM and ARV were associated with worse Digit Symbol Coding test score. GV measures were not associated with change in CASI performance among 1834 participants with repeat CASI data 6 years later. However, among 229 participants with incident T2D, the SDG and VIM were associated with decline in CASI (-1.7 [95% CI: -3.1, -0.3] and -2.1 [-3.7, -0.5] points, respectively). In contrast, single-timepoint glucose and HbA1c were not associated with CASI decline among participants with or without incident T2D.
CONCLUSION: Higher visit-to-visit GV over 16 to 18 years is associated with worse cognitive performance in the general population, and with modest global cognitive decline in participants with T2D.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 109(2023), 1 vom: 21. Dez., Seite e243-e252 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schaich, Christopher L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aging |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgad444 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359976301 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359976301 | ||
| 003 | DE-627 | ||
| 005 | 20240425232321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgad444 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM359976301 | ||
| 035 | |a (NLM)37497618 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schaich, Christopher L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Visit-to-Visit Glucose Variability, Cognition, and Global Cognitive Decline |b The Multi-Ethnic Study of Atherosclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a CONTEXT: Higher visit-to-visit glucose variability (GV) is associated with dysglycemia and type 2 diabetes (T2D), key risk factors for cognitive decline | ||
| 520 | |a OBJECTIVE: Evaluate the association of GV with cognitive performance and decline in racially/ethnically diverse older populations with and without T2D | ||
| 520 | |a METHODS: We calculated the standard deviation of glucose (SDG), average real variability (ARV), and variability independent of the mean (VIM) among 4367 Multi-Ethnic Study of Atherosclerosis participants over 6 clinical examinations. Participants completed a cognitive assessment at the fifth examination, and a subset completed a second assessment 6 years later. We used multivariable linear regression to estimate the association of intraindividual GV with cognitive test scores after adjustments for cardiovascular risk factors and mean glucose level over the study period | ||
| 520 | |a RESULTS: Two-fold increments in the VIM and SDG were associated with worse Cognitive Abilities Screening Instrument (CASI) performance, while two-fold increments in VIM and ARV were associated with worse Digit Symbol Coding test score. GV measures were not associated with change in CASI performance among 1834 participants with repeat CASI data 6 years later. However, among 229 participants with incident T2D, the SDG and VIM were associated with decline in CASI (-1.7 [95% CI: -3.1, -0.3] and -2.1 [-3.7, -0.5] points, respectively). In contrast, single-timepoint glucose and HbA1c were not associated with CASI decline among participants with or without incident T2D | ||
| 520 | |a CONCLUSION: Higher visit-to-visit GV over 16 to 18 years is associated with worse cognitive performance in the general population, and with modest global cognitive decline in participants with T2D | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a aging | |
| 650 | 4 | |a cognition | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a fasting glucose | |
| 650 | 4 | |a glucose variability | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Bancks, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Hayden, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Jingzhong |e verfasserin |4 aut | |
| 700 | 1 | |a Rapp, Stephen R |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Alain G |e verfasserin |4 aut | |
| 700 | 1 | |a Heckbert, Susan R |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Timothy M |e verfasserin |4 aut | |
| 700 | 1 | |a Mongraw-Chaffin, Morgana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 109(2023), 1 vom: 21. Dez., Seite e243-e252 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2023 |g number:1 |g day:21 |g month:12 |g pages:e243-e252 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgad444 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2023 |e 1 |b 21 |c 12 |h e243-e252 | ||